Effect of Eltrombopag on Response to Immunosuppressive Therapy in Patients with Transfusion-Dependent Non-Severe Aplastic Anemia.
10.19746/j.cnki.issn.1009-2137.2023.03.030
- Author:
Ying LIN
1
,
2
;
Rong-Dong ZHANG
3
;
Zeng-Hua LIN
4
;
Qi CHEN
3
;
Ren-Li CHEN
3
Author Information
1. Department of Hematology, Ningde Municipal Hospital of Ningde Normal University, Ningde 352100, Fujian Province, China,E-mail：linying806@
2. com.
3. Department of Hematology, Ningde Municipal Hospital of Ningde Normal University, Ningde 352100, Fujian Province, China.
4. Department of Hematology, The Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
- Publication Type:Journal Article
- Keywords:
cyclosporine;
efficacy;
eltrombopag;
non severe aplastic anemia;
transfusion dependent
- MeSH:
Humans;
Anemia, Aplastic/therapy*;
Retrospective Studies;
Treatment Outcome;
Cyclosporine/therapeutic use*;
Immunosuppression Therapy;
Immunosuppressive Agents/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(3):823-829
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To compare the efficacy of eltrombopag combined with cyclosporine A (CsA) and CsA alone in patients with transfusion-dependent non-severe aplastic anemia (TD-NSAA).
METHODS:The clinical data of 76 patients with treatment-naive TD-NSAA in Ningde Municipal Hospital of Ningde Normal University and Affiliated Hospital of Nantong University from December 2017 to June 2021 were retrospectively analyzed. Among them, 45 cases were treated with eltrombopag combined with CsA, and 31 patients with compatible baseline characters were treated with CsA alone. The efficacy of patients between the two groups was compared, and the factors affecting the curative effects were also analyzed.
RESULTS:There were significant differences in hematological response (HR) and complete response(CR) rates between the two groups at 3, 6, 12 months, and follow-up endpoint of treatment (P<0.05). With the prolongation of eltrombopag treatment time, the curative effect increased gradually, and the patients achieved more CR and HR rates by the end of the follow-up period. Simultaneously, with the increase in the maximum stable dose of eltrombopag, the HR rate increased gradually. The megakaryocyte count in eltrombopag group was higher than that in control at 6 and 12 months (P<0.05). Compared with the control group, the median time of platelet transfusion independence in eltrombopag group was more shorter (P=0.018), and the median platelets transfusion volume was lower (P=0.009). At 3, 6, 12 months after eltrombopag, the change of platelet in eltrombopag group was higher than that in the control group (P<0.05). Analysis of related factors affecting the efficacy showed that sex, age, iron overload, platelet count before treatment had no effect on the efficacy, and the median maximum stable dosage and the administration period for eltrombopag were related to the curative effect. The patients of eltrombopag group experienced adverse events of varying degrees, but the reactions were mild and mostly tolerated.
CONCLUSION:Eltrombopag can effectively improve the hematopoietic response and promote platelet recovery for TD-NSAA patients with relatively more residual hematopoietic cells, and it is safe and well tolerated.
